Andere talen BioCryst Pharmaceuticals, Inc.

Aandelen

BCRX

US09058V1035

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 15-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,590 ^USD	+0,26%		-1,43%	+0,93%

12/12	Sectornieuws: Gezondheidszorgaandelen stijgen licht in de voorbeurshandel op vrijdag	MT
12/12	Beursgenoteerde fondsen lager, aandelenfutures gemengd voorbeurs op vrijdag nu Broadcom-resultaten zorgen verdiepen	MT

Andere talen

Sector Update: Health Care Stocks Edge Higher Premarket Friday	12/12
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday as Broadcom Results Deepen Fears	12/12
Biocryst Pharmaceuticals, Inc. Announces Fda Approval of Orladeyo® (Berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with Hae Aged 2 to <12 Years	12/12
BioCryst Receives FDA Approval for Orladeyo For Young Hereditary Angioedema Patients	12/12
BioCryst Gets FDA OK for Pediatric Use of Orladeyo	12/12
FDA approves BioCryst's oral pellet version of swelling disorder drug for children	12/12
FDA expands approval of BioCryst's rare disease drug for use in young children	12/12
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years	12/12
Biocryst Pharmaceuticals, Inc. Announces Retirement of Nancy J. Hutson, Ph.D. and Election of Vincent J. Milano as Next Chair of the Board	11/12
Biocryst reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	04/12
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/12
Biocryst receives early termination of Hart-Scott-Rodino waiting period for Astria acquisition	03/12
BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle	03/12
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition	03/12
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO	06/11
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)	06/11
BioCryst to Present at Upcoming Investor Conference	05/11
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/11
BioCryst Pharmaceuticals, Inc. Appoints Ron Dullinger as Chief Commercial Officer, Effective January 1, 2026	03/11
BioCryst Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2025	03/11
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	03/11
BioCryst Pharmaceuticals' Q3 Non-GAAP Earnings, Revenue Increase	03/11
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q3 Revenue $159.4M, vs. FactSet Est of $163.0M	03/11
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $0.16 per Share, vs. FactSet Est of $0.07	03/11
BioCryst Pharma Q3 operating profit up, raises FY ORLADEYO sales guidance	03/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioCryst Pharmaceuticals, Inc.

Aandelen

BCRX

US09058V1035

Biotechnologie & Medisch Onderzoek

Andere talen

Filters